Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of frexalimab versus teriflunomide in relapsing multiple sclerosis
2024-514343-29-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 35
01
Overview
Phase 3, randomised, double-blind trial of frexalimab in multiple sclerosis (MS) (2 arms), sponsored by Sanofi. Primary endpoint: Annualized relapse rate. Planned start Nov 2024; status: authorised.
02
Drugs
frexalimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-514343-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514343-29-00.